$TWST

Leproust Emily M. sold $158K of TWST

Leproust Emily M. (Chief Executive Officer) sold 2,265 shares of Twist Bioscience Corp (TWST) at $69.84 ($0.16M total) on 2026-06-08.

Original reporting
SEC EDGAR · Leproust Emily M.
Published Jun 10, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The only new information is the reported open-market sale size, price, and post-transaction holdings; it may marginally influence sentiment but does not change company fundamentals on its own.

02

Market read

Traders may monitor TWST for follow-on insider activity, but this single modest sale is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; however, absence of a stated plan does not prove information trading—context (other sales, compensation, tax events) is not provided.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-10 (covers sale dated 2026-06-08)

Background

The article is an SEC Form 4 insider transaction disclosure for Twist Bioscience CEO Emily M. Leproust.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

CEO Emily M. Leproust filed an open-market sale of 2,265 TWST shares for about $158.2K on 2026-06-08 (Form 4).

Expected impact

Likely limited near-term impact; treat as a small sentiment signal rather than a fundamental catalyst.

Evidence & confidence

Form 4 insider sales are typically low-signal unless paired with unusual size, acceleration, or accompanying corporate/regulatory developments; this disclosure is modest in value and does not indicate a new business event.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Insider sales can be planned for diversification/taxes and may not reflect bearish fundamentals, especially when not tied to a corporate event.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Emily M. Leproust

    CEO and director who sold 2,265 shares.

Related articles

$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.